GS
TGTX icon

GTS Securities’s TG Therapeutics TGTX Stock Holding History

GTS Securities’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-79,400
Closed -$1.86M – 3822
2024
Q3 		$1.86M Buy
79,400
+5,300
+7% +$116K ﹤0.01% 1619
2024
Q2 		$1.32M Sell
74,100
-141,600
-66% -$2.26M ﹤0.01% 1825
2024
Q1 		$3.28M Buy
215,700
+60,600
+39% +$965K 0.01% 1140
2023
Q4 		$2.65M Buy
155,100
+33,300
+27% +$387K ﹤0.01% 1449
2023
Q3 		$1.02M Buy
+121,800
New +$1.7M ﹤0.01% 2005

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

GTS Securities's TGTX Position: Q2 2026 in Review

GTS Securities sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 7,139 shares — an estimated $237K sold.

GTS Securities first reported a position in TGTX in Q3 2023 and held it in 6 quarters. The position peaked at $7.02M in Q4 2023. 430 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • GTS Securities reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
  • GTS Securities sold 7,139 TG Therapeutics shares in Q2 2026, an estimated $237K.
  • GTS Securities first reported a position in TG Therapeutics in Q3 2023 and held it in 6 quarters.
  • GTS Securities's TG Therapeutics position peaked at $7.02M in Q4 2023.
  • 430 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.